Evidence map›Paper›PMID 28792271›Full record

ReviewTranscription2018

Is TFIIH the new Achilles heel of cancer cells?

Pietro Berico, Frédéric Coin

Open access · bronzeAbstract readReview
In one paragraph

Review in Transcription, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Pietro Bericoa IGBMC, Department of Functional Genomics and Cancer , CNRS/INSERM/University of Strasbourg , Strasbourg , France.ORCID 0000-0001-8034-0790
Frédéric Coina IGBMC, Department of Functional Genomics and Cancer , CNRS/INSERM/University of Strasbourg , Strasbourg , France.
Centre National de la Recherche Scientifique · FR

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

TFIIH is a 10-subunit complex involved in transcription and DNA repair. It contains several enzymatic activities including a ATP-dependent DNA translocase in XPB and a cyclin-dependent kinase in CDK7. Recently the discovery of several XPB and CDK7 inhibitors with specific impact on the transcriptional addiction of many tumors pinpointed these activities as potential target in cancer chemotherapy. Unexpectedly a basal transcription factor involved in global mRNA expression now emerges a one of the most clinically promising Achilles heels of cancerous cells. These inhibitors also proved to be useful tools to unveil new functions of TFIIH in gene expression.

Indexed as

Cyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesDNA-Binding ProteinsDNA HelicasesDNA RepairHumansNeoplasmsRNA, MessengerTranscription Factor TFIIHTranscription, GeneticCDK7 protein, humanCyclin-Dependent Kinase-Activating KinaseCyclin-Dependent KinasesDNA-Binding ProteinsDNA HelicasesRNA, MessengerTranscription Factor TFIIHXPBC-ERCC-3 proteinDNA repairgenomic instabilityhelicaseTFIIH

Identifiers

PMID28792271
PMCPMC5791811
OpenAlexW2744740843

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.